Cardiovascular Drugs and Therapy

, Volume 6, Issue 1, pp 25–27 | Cite as

Drugs affecting plasma fibrinogen levels

  • Giovanni di Minno
  • Mario Mancini
State-of-the-Art Lectures


Current knowledge indicates that high plasma levels of fibrinogen help predict stroke and myocardial infarction. It is known that plasma fibrinogen is synthesized in the liver, that interleukin-6 (IL-6) affects this synthesis, and that, when exposed to appropriate stimuli, monocytes generate a variety of monokines, including IL-6. It is also known that prolonged administration of N-3 fatty acids, ticlopidine, fibrates, pentoxifylline, or alcohol lower plasma fibrinogen levels. The mechanism(s) involved in this effect are poorly understood. However, in view of the role of IL-6 and monocytes in the regulation of plasma fibrinogen levels, it is conceivable that the lowering effect of these drugs involves effects on some steps of the regulatory machinery. In addition to fibrinogen, IL-6 regulates the synthesis of other acutephase proteins. This raises the question of whether high plasma fibrinogen levels do reflect the response of an acutephase reactant to the severity of the atherosclerotic vascular damage taking place. Current evidence is inconclusive with respect to this possibility. On the other hand, the epidemiological data available indicate that measurements of plasma fibrinogen should be included in the cardiovascular riskfactor profile. In view of this, we believe that information emerging from population-based studies in which plasma fibrinogen is measured is important to identify appropriate directions to be followed to address unsolved issues in the area.

Key Words

fibrinogen acute-phase response genetic inheritance drugs prediction of stroke and myocardial infarction 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Di Minno G, Mancini M. Measuring plasma fibrinogen to predict stroke and myocardial infarction. Arteriosclerosis 1990;10:1–7.PubMedGoogle Scholar
  2. 2.
    Crabtree GR, Courtois G, Morgan JG. Cellular and nuclear factors coordinating the expression of the three fibrinogen genes. In: Verstraete M, Vermylen J, Lijenen HR, and Arnout J, eds. Thrombosis and haemostasis 1987. Leuven: International Society on Thrombosis and Haemostasis and Leuven University Press, 1987.Google Scholar
  3. 3.
    Yu S, Sher B, Kudryk B, Redman CM. Intracellular assembly of human fibrinogen. J Biol Chem 1983;258:13407–13410.PubMedGoogle Scholar
  4. 4.
    Yu S, Sher B, Kudryk B, Redman CM. Intracellular assembly of human fibrinogen. J Biol Chem 1984;259:10574–10581.PubMedGoogle Scholar
  5. 5.
    Le J, Vilcek J. Interleukin-6: A multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest 1989;61:588–602.PubMedGoogle Scholar
  6. 6.
    Heinrich PC, Castell JV, Andus T. Interleukin 6 and the acute phase response. Biochem J 1990;265:621–636.PubMedGoogle Scholar
  7. 7.
    Evans E, Courtois GM, Kilian P, et al. Induction of fibrinogen and a subset of acute phase response genes involves a novel monokine which is mimicked by phorbol esters. J Biol Chem 1987;262:10850–10854.PubMedGoogle Scholar
  8. 8.
    Hostmark AT, Bjerkedal T, Kierulf P, et al. Fish oil and plasma fibrinogen. Br Med J 1988;297:180–181.CrossRefGoogle Scholar
  9. 9.
    Radack K, Deck C, Huster G. Dietary supplementation with low-dose fish oils lowers fibrinogen levels: A randomized, double-blind controlled study. Ann Intern Med 1989;11: 757–758.Google Scholar
  10. 10.
    Burr ML, Fehiky AM, Gilbert JF, et al. Effects of changes in fat, fish and fibre intakes on death and myocardial infarction: Diet and reinfarction trial (DART). Lancet 1989;2:757–761.PubMedCrossRefGoogle Scholar
  11. 11.
    Sperling RJ, Robin JL, Kylander KA, et al. The effects of n-3 polyunsaturated fatty acids on the generation of platelet activating factor-acether by human monocytes. J Immunol 1987;139:4186–4191.PubMedGoogle Scholar
  12. 12.
    Endres S, Ghorbani R, Kelley VE, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989;320:265–271.PubMedCrossRefGoogle Scholar
  13. 13.
    Meade TW, Imeson J, Stirling Y. Effects of changes in smoking and other characteristics on clotting factors and the risk of ischaemic heart disease. Lancet 1987;2:986–989.PubMedCrossRefGoogle Scholar
  14. 14.
    Hamsten A, Iselius L, De Faire U, Blomback M. Genetic and cultural inheritance of plasma fibrinogen concentration. Lancet 1987;1:988–990.CrossRefGoogle Scholar
  15. 15.
    Bagasra O, Howeedy A, Kajdacsy-Balla A. Macrophage function in chronic experimental alcoholism. Modulation of surface receptors and phagocytosis. Immunology 1988;65: 405–409.PubMedGoogle Scholar
  16. 16.
    Balsano F, Coccheri S, Libretti A, et al. Ticlopidine in the treatment of intermittent claudication: A 21-month doubleblind trial. J Lab Clin Med 1989;114:84–91.PubMedGoogle Scholar
  17. 17.
    Takamatsu S, Sato K, Takamatsu M, et al. A two year follow up study on blood constituents in aged arteriosclerotic patients treated with pentoxifylline. Proceedings of the 28th International Congress of Physiological Sciences, Tubingen, West Germany, 1980.Google Scholar
  18. 18.
    Angelkort B, Pirnay D, Kieswater H, Maurin N. Hemodilution and pentoxifylline effects on muscle blood flow and blood fluidity in chronic arterial occlusive disease. Vasc Med 1983;1:150–158.Google Scholar
  19. 19.
    Muggeo M, Calabro A, Businaro V, et al. Blood clotting, fibrinolytic and haemorheological parameters in ischaemic vascular disease: The effects of pentoxifylline in the treatment of acute vascular disease. Pharmacotherapeutica 1983;3(Suppl 1):74–90.Google Scholar
  20. 20.
    Ott E, Fazekas F, Lechner H. Haemorheological effects of pentoxifylline in disturbed blood flow behaviour in patients with cerebrovascular disease. Neurology 1983;22(Suppl 1): 105–107.Google Scholar
  21. 21.
    Di Perri T, Carandente O, Vittoria O, et al. Studies on the clinical pharmacology and therapeutic efficacy of pentoxifylline in peripheral obstructive arterial disease. Angiology 1984;35:427–435.PubMedGoogle Scholar
  22. 22.
    Strano A, Davi' G, Avellone G, et al. Double-blind crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs. Angiology 1984;35:439–446.Google Scholar
  23. 23.
    Watson SP, McConnel RT, Lapetina EG. The formation of inositol phosphates in human platelets by thrombin is inhibited by prostacyclin. J Biol Chem 1984;259:13199–13203.PubMedGoogle Scholar
  24. 24.
    Andersen P, Smith P, Seljeflot I, et al. Effects of gemfibrozil on lipids and haemostasis after myocardial infarction. Thromb Haemost 1990;63:174–177.PubMedGoogle Scholar
  25. 25.
    Niort G, Bulgarelli A, Cassader M, Pagano G. Effect of short term treatment with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenemic patients. Atherosclerosis 1988;71:113–119.PubMedCrossRefGoogle Scholar
  26. 26.
    Ciuffetti G, Orecchini G, Siepi D, et al. Hemorheological activity of gemfibrozil in primary hyperlipidemias. In: Paoletti R, et al., eds. Drugs affecting lipid metabolism. Berlin: Springer-Verlag, 1987:372–375.Google Scholar
  27. 27.
    Endemann G, Pronzcuk A, Friedman G, et al. Monocyte adherence to endothelial cells in vitro is increased by beta-VLDL. Am J Path 1987;126:1–6.PubMedGoogle Scholar
  28. 28.
    Poli V, Cortese R. Interleukin-6 induces a liver-specific nucler protein that binds to the promoter of acute-phase genes. Proc Natl Acad Sci USA 1989;86:8202–8206.PubMedCrossRefGoogle Scholar
  29. 29.
    Poli V, Mancini FP, Cortese R. IL-6DBP, a nuclear protein involved in interleukin-6 signal transduction, defines a new family of leucine zipper proteins related to C/EBO. Cell 1990;63:643–653.PubMedCrossRefGoogle Scholar
  30. 30.
    Humphries SE, Cook M, Dubowitz M, et al. Role of genetic variation at the fibrinogen locus in determination of plasma fibrinogen concentrations. Lancet 1987;1:1452–1455.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1992

Authors and Affiliations

  • Giovanni di Minno
    • 1
  • Mario Mancini
    • 1
  1. 1.Clinica MedicaIstituto di Medicine Interna e Malattie Dismetaboliche, Nuovo PoliclinicoNapoliItaly

Personalised recommendations